


Human Protease and Use of Such Protease for  
Pharmaceutical Applications and for Reducing  
the Allergenicity of Non-Human Proteins  
David A. Estell  
Docket No. GC532-C1  
Sheet 1 of 13



**FIG.\_1A**

Human Protease and Use of Such Protease for  
 Pharmaceutical Applications and for Reducing  
 the Allergenicity of Non-Human Proteins  
 David A. Estell  
 Docket No. GC532-C1  
 Sheet 2 of 13

1 GGTCTACTAAATTATTCCATACTATACAGAAATACTGCTATGGTTATTCTGCAATGAAAAAGGGAGGGATAAGA GTG

5 P

⑤

③

④

107 RBS Met

PRE

99 Arg Gly Lys Lys Val Ile Ser Leu Leu Phe Ala Leu Ala Leu Ile Phe Thr Met Ala Phe Gly Ser Thr Ser  
 AGA GGC AAA AAA GTC TGG ATC AGT TGG CTG ATT GCT TTA ATC TTT GCG TTA ATC TTT ACG ATG GCG TTC GGC AGC ACA TCC

80 Ser Ala Gln Ala Ala Gly Lys Ser Asn Gly Glu Lys Lys Tyr Ile Val Gly Phe Lys Val Gln Thr Met Ser Thr Met  
 174 TCT GCC CAG GCG GCA GGG AAA TCA AAC GGC AAC AAA GAT GTC ATT TCT GAA AAA GGC GAA AAA TAT ATT GTC GGG TTT AAA CAG ACA ATG AGC ACG ATG

70 PRO

50 Ser Ala Ala Lys Lys Ile Asp Val Ile Ser Glu Lys Gly Lys Val Gln Phe Lys Tyr Val Asp Ala  
 249 AGC GCC GCT AAG AAG AAA GAT GTC ATT TCT GAA AAA GCT GTC AAA GAA GAA AAA GAC CCG AGC GTC GCT TAC GTT GAA GAA GAT

40

30 Ala Ser Ala Thr Leu Asn Glu Lys Ala Val Lys Glu Leu Lys Asp Pro Ser Val Ala Tyr Val Glu Glu Asp  
 324 GCT TCA GCT ACA ATT AAC GAA AAA GCT GTC AAA GAA GAA AAA GAC CCG AGC GTC GCT TAC GTT GAA GAA GAT

20 His Val Ala His Ala Tyr Ala Gln Ser Val Pro Tyr Gly Val Ser Gln Ile Lys Ala Pro Ala Leu His Ser Gln  
 399 CAC GTA GCA CAT GCG TAC GCG CAG TCC GTG CCT TAC GGC GTA TCA CAA ATT AAA GCC CCT GCT CTC TAC TCT CAA

1 MAT

1

10

20 Gly Tyr Thr Gly Ser Asn Val Lys Val Ala Val Ile Asp Ser Gly Ile Asp Ser Ser His Pro Asp Leu Lys Val  
 474 GGC TAC ACT GGA TCA ATT GTT AAA GTC GCG GTT ATC GAC AGC GGT ATC GAT TCT TCT CAT CCT GAT TTA AAG GTA

FIG.- 1B - 1

Human Protease and Use of Such Protease for  
Pharmaceutical Applications and for Reducing  
the Allergenicity of Non-Human Proteins  
David A. Estell  
Docket No. GC532-C1  
Sheet 3 of 13

**FIG. - 1B - 2**

250 Gln Val Arg Ser Ser Gln 250 Gln Val Arg Ser Ser Gln Glu Asn Thr Thr Lys Leu Gly Asp Ser Phe Tyr Tyr Lys Gly Leu Ile Asn  
1149 CAA GTC CGC AGC AGT TTA GAA AAC ACC ACT ACA AAA CTT GAT TCT TAC TAC TAC TAC TAC TAC TAC TAC AAC  
270 Val Gln Ala Ala Gln OC 275 **TERM**  
1224 GTA CAG GCG GCA GCT CAG TAA AACATAAAAAAACCGGGCTTGGCCCCGGCTTGGCTTTATTTTCTCCGATGTTCAATCCGTC  
1316 ATATCGACGGATGGCTCCCTCTGAAAATTTAACGAGAAACGGGGTTGACCCGGCTAGTCCGTAACGGCCAAGTCCGAAACGTCATGGCG  
1416 CTTCGGTTCCGGTCAAGCTCAATGCCGTAACGGTGGGGCTTCTGATAACGGAGACGGCATTCGTAATGGATC

**FIG.-1B - 3**

FIG.-1B - 1

FIG.-1B - 2

FIG.-1B - 3

**FIG.-1B**

CONSERVED RESIDUES IN SUBTILISINS FROM  
BACILLUS AMYLOLIQUEFACIENS

1	10	20
A Q S V P . G . . . .	A P A . H . . G	
21	30	40
. T G S . V K V A V . D . G . . . .	H P	
41	50	60
D L . . . G G A S . V P . . . . .	Q D	
61	70	80
. N . H G T H V A G T . A A L N N S I G		
81	90	100
V L G V A P S A . L Y A V K V L G A . G		
101	110	120
S G . . S . L . . G . E W A . N . . . .		
121	130	140
V . N . S L G . P S . S . . . . A . .		
141	150	160
. . . . . G V . V V A A . G N . G . . .		
161	170	180
. . . . . Y P . . Y . . . . A V G A .		
181	190	200
D . . N . . A S F S . . G . . L D . . A		
201	210	220
P G V . . Q S T . P G . . Y . . . N G T		
221	230	240
S M A . P H V A G A A A L . . . K . . .		
241	250	260
W . . . Q . R . . L . N T . . . L G . . .		
261	270	
. . Y G . G L . N . . A A . .		

**FIG.-2**

COMPARISON OF SUBUTILISIN SEQUENCES FROM:  
*B.amyloliquefaciens*  
*B.subtilis*  
*B.licheniformis*  
*B.lentus*

01	A Q S V P P Y G V S	10	Q I K A P A L H S Q	20	G Y T G S N V K V A	30	D S S G I D S S H P	
A Q S V P P Y G I S	Q I K A P A L H S Q	G Y T G S N V K V A	V I D S S H P	V I D S S H P	V I D S S H P	V I D S S H P		
A Q T V P P Y G I P	L I R A D K V Q A Q	G F K G A N V K V A	V L D T G I Q A S H P	V L D T G I Q A S H P	V L D T G I Q A S H P	V L D T G I Q A S H P		
A Q S V P P W G I S	R V Q A P A A H N R G	G L T G S G V K V A	V L D T G I S T * H P	V L D T G I S T * H P	V L D T G I S T * H P	V L D T G I S T * H P		
41	D L K V A G G A S M V P	50	S E T N P P Q D N N S	60	H G T H V A G T V A A	70	L N N S I G	
D L N V R G G A S P V P	S E T N P Y Q D G S S	H G T H V A G T I A A	L N N S I G	H G T H V A G T I A A	L N N S I G	H G T H V A G T I A A		
D L N V V G G A S P V P	* T D G N G H G T H V A	G T H V A G T V A A	L D N T T G	G T H V A G T V A A	L D N T T G	G T H V A G T V A A		
D L N I R G G A S P V P	G E * P S T Q D G N G H	G T H V A G T I A A	L N N S I G	G T H V A G T I A A	L N N S I G	G T H V A G T I A A		
81	V L G V A P S A S L Y A V K V L G A D G S G Q Y S W	90	100	110	120	130	140	150
V L G V S P S A S L Y A V K V L D S T G S G Q Y S W	I N G I E W A I A N N M D	V L G V A P S V S L Y A V K V L N S S G S Y S S G I V S C I E W A T T N G M D	V L G V A P S A E L Y A V K V L G A S G S G S V S S I A Q G L E W A G N N G M H	V I N M S L G G P S A A L K A A V D K A V A S G V V V A A A G N E G T S G	V I N M S L G G P T G S T A L K T V V D K A V S S G I V V A A A G N E G S S G	V I N M S L G G A S G S T A M K Q A V D N A Y A R G V V V A A A G N S G N S G	V A N L S L G S P S P S A T L E Q A V N S A T S R G V L V V A A S G N S G A G S	

FIG.-3A

## Human Protease and Use of Such Protease for Pharmaceutical Applications and for Reducing the Allergenicity of Non-Human Proteins

the Acceptability of No  
David A. Estell  
Docket No. GC532-C1  
Sheet 7 of 13

1161	1170	1180	1190	1201	1210	1220	1230	1241	1250	1260	1270
S S S S T T V G Y P G K Y P S V I A V G A V D S S N Q R A S F S S V G P E L D V M A	S S T T V G Y P A K Y P S T I A V G A V N S S N Q R A S F S S A G S E L D V M A	S T N T I G Y P A K Y D S S V I A V G A V D S N S N R A S F S S V G A E L E V M A	* * * * * P A R Y A N A M A V G A T D Q N N N R A S F S S Q Y G G A G L D I V A	P G V S I Q S T L P G N K Y G A Y N G T S M A S P H V A G A A A L I L S K H P N	P G V S I Q S T L P G G T Y G A Y N G T S M A T P H V A G A A A L I L S K H P T	P G A G V Y S T Y P T N T Y A T L N G T S M A S P H V A G A A A L I L S K H P N	P G V N V Q S T Y P G S T Y A S L N G T S M A T P H V A G A A A L V K Q K N P S	W T N T Q V R S S L E N T T K L G D S S F Y Y G K G L I N V Q A A A Q	W T N A Q V R D R L E S T A T Y L G N S F Y Y G K G L I N V Q A A A Q	W T N S Q V R N R L S S T A T Y L G S S F Y Y G K G L I N V E A A A Q	W S S N V Q T R N H L K N T A T S L G S T N L Y G S G L V N A E A A T R

FIG.-3

FIG.-3B




FIG. 4

Human Protease and Use of Such Protease for  
Pharmaceutical Applications and for Reducing  
the Allergenicity of Non-Human Proteins

David A. Estell

Docket No. GC532-C1

Sheet 9 of 13




FIG. 5

Human Protease and Use of Such Protease for  
Pharmaceutical Applications and for Reducing  
the Allergenicity of Non-Human Proteins  
David A. Estell  
Docket No. GC532-C1  
Sheet 10 of 13

MKLVNIWLLLVLVLLCGKKHLGDRLEKKSF EKAPCPGCSHLTLKVEFSSTVVEYEYIVAFNGYFT  
AKARNSFISSALKSSEVDNWRIIPRNNPSSDYP PSDFEVIQIKEKQAGLLTLEDHPNIKRVTPQR  
KVFRSLKYAESDPTVPCNETRWSQWQSSRPLRRASLISLGSGFWHATGRHSSRLLRAIPROVAQ  
TLQADVLWQMGYTGANVRVAVFDTGLSEKHPFKNVKERTNWTNERTLDDGLGHGTFVAGVIASM  
RECQGFAPDAELHIFRVFTNNQVSYTSWFLDAFN YAI LKKIDVLNLSIGGPDFMDHPFVDKVWEL  
TANNVIMVSAIGNDGPLYGTLNNPADQMDVIGVGGIDFEDNIARFSSRGMTTWELPGGYGRMKPD  
IVTYGAGVRGSGVKGGCRALSGTSVASP VVAGAVTLLVSTVQKRELVPASMKQALIASARRLPG  
VNMFEQGHGKLDLLRAYQILNSYKPQASLSPSYIDLTECPYMWPYCSQPIYYGGMPTVVNVTILN  
GMGVTGRIVDKPDWQPYLPQNGDNIEVAFSYSSVLWPWSGYL AISISVTKKAASWEGIAQGHVMI  
TVASPAETESKNGAEQTSTVKLP IKVKIIPTPPRSKRVLWDQYHNLRYPPGYFPRDNLRMKNDPL  
DWNGDHIHTNFRDMYQHLLRSMGYFVEVLGAPFTCFDASQYGTLLMVDSEEEYFPEEIAKLRRDVD  
NGLSLVIFSDWYNTSVMRKVKFYDENTRQWWMPDTGGANI PALNELL SVWNMGFS DGLYEGEFTL  
ANHDMMYASGCSIAKFPEDGVVITQTFKDQGLEVLKQETAVVENVPILGLYQIPAEGGGRIVLYG  
DSNCLDDSHRQKDCFWLLDALLQYTSYGVTPPSLSHSGNRQPPSGAGSVTPERMEGNHLHRYSK  
VLEAHLGDPKPRPLPACPRLSWAKPQPLNETAPSNLWKHQKLLSIDLDKVVLPNFRSNRPQVRPL  
SPGESCAWDI PGGIMPGRYNQEVGQTIPVFAFLGAMVLAFFVVQINKAKSRPKRRKPRVKR PQL  
MQQVHPPKTPSV

**FIG. 6**

1	A12	IKDFHVYFRESRDA	49	E12	SATSRGVLVAAASGN
2	A11	LEQAVNSATSRGVLV	50	E11	SRGVLVAAASGNNSGA
3	A10	AQSVPWGISRQAPA	51	E10	VLVVAASGNSGAGS I
4	A9	VPWGISRQAPAHHNAH	52	E9	VAASGNSGAGSISYP
5	A8	GISRVQAPAHHNRGL	53	E8	SGNSGAGSISYPARY
6	A7	RVQAPAHHNRGLTGS	54	E7	SGAGSISYPARYANA
7	A6	APAAHNRGLTGSVVK	55	E6	GSISYPARYANAMAV
8	A5	AHNRLGTGSVVKAV	56	E5	SYPARYANAMAVGAT
9	A4	RGLTGSVVKAVLDT	57	E4	ARYANAMAVGATDQN
10	A3	TGSGVVKAVLDTG	58	E3	ANAMAVGATDQNNR
11	A2	GVKVAVLDTGISTHP	59	E2	MAVGATDQNNNRASF
12	A1	VAVLDTGISTHPDLN	60	E1	GATDQNNNRASF SQY
13	B12	LDTGISTHPDLNIRG	61	F12	DQNNNRASF SQY GAG
14	B11	GISTHPDLNIRGGAS	62	F11	NNRASF SQY GAGLDI
15	B10	THPDLNIRGGASFVP	63	F10	ASFSQY GAGLDIVAP
16	B9	DLNIRGGASFVPGEP	64	F9	SQY GAGLDIVAPGVN
17	B8	IRGGASFVPGEPSTQ	65	F8	GAGLDIVAPGVNVQS
18	B7	GASFVPGEPSTQDGN	66	F7	LDIVAPGVNVQSTYP
19	B6	FVPGEPSTQDGNHG	67	F6	VAPGVNVQSTYPGST
20	B5	GEPSTQDGNHGHTHV	68	F5	GVNVQSTYPGSTYAS
21	B4	STQDGNHGHTHVAGT	69	F4	VQSTYPGSTYASLNG
22	B3	DGNHGHTHVAGTIAA	70	F3	TYPGSTYASLNGTSM
23	B2	GHGHTHVAGTIAALNN	71	F2	GSTYASLNGTSMATP
24	B1	THVAGTIAALNNSIG	72	F1	YASLNGTSMATPHVA
25	C12	AGTIAALNNSIGVLG	73	G12	LNGTSMATPHVAGAA
26	C11	IAALNNSIGVLGVAP	74	G11	TSMATPHVAGAAALV
27	C10	LNNSIGVLGVAPSAE	75	G10	ATPHVAGAAALVKQK
28	C9	SIGVLGVAPSAELYA	76	G9	HVAGAAALVKQKNPS
29	C8	VLGVAPSAELYAVKV	77	G8	GAAALVKQKNPSWSN
30	C7	VAPSAELYAVKVLGA	78	G7	ALVKQKNPSWSNVQI
31	C6	SAELYAVKVLGASGS	79	G6	KQKNPSWSNVQIRNH
32	C5	LYAVKVLGASGGSV	80	G5	NPSWSNVQIRNHILKN
33	C4	VKVLGASGGSVSSI	81	G4	WSNVQIRNHILKNTAT
34	C3	LGASGGSVSSIAQG	82	G3	VQIRNHILKNTATSLG
35	C2	SGSGSVSSIAQGLEW	83	G2	RNHLKNTATSLGSTN
36	C1	GSVSSIAQGLEWAGN	84	G1	LKNTATSLGSTNLYG
37	D12	SSIAQGLEWAGNNGM	85	H12	TATSLGSTNLYGSGL
38	D11	AQGLEWAGNNGMHVA	86	H11	SLGSTNLYGSGLVNA
39	D10	LEWAGNNGMHVA	87	H10	STNLYGSGLVNAEAA
40	D9	AGNNGMHVA	88	H9	NLYGSGLVNAEATR
41	D8	LSLGMHVA			
42	D7	NGMHVANL			
43	D6	LSLGMHVA			
44	D5	NGMHVANL			
45	D4	LSLGMHVA			
46	D3	NGMHVANL			
47	D2	LSLGMHVA			
48	D1	NGMHVANL			

FIG. 7

1	A12	IKDFHVYFRESRDAG	49	E12	KKIDVLNLSIGGPDF
2	A11	DAELHI FRVFTNNQV	50	E11	DVLNLSIGGPDFMDH
3	A10	PLRRASLSLGSGFWH	51	E10	NLSIGGPDFMDHPFV
4	A9	RASLSLGSGFWHATG	52	E9	IGGPDFMDHPFVDKV
5	A8	LSLGSGFWHATGRHS	53	E8	PDFMDHPFVDKVVWEL
6	A7	GSGFWHATGRHSSRR	54	E7	MDHPFVDKVVWELTAN
7	A6	FWHATGRHSSRLLR	55	E6	PFVDKVVWELTANNVI
8	A5	ATGRHSSRLLRAIP	56	E5	DKVWELTANNVIMVS
9	A4	RHSSRLLRAIPRQV	57	E4	WELTANNVIMVSAIG
10	A3	SRRLLRAIPRQVAQT	58	E3	TANNVIMVSAIGNDG
11	A2	LLRAIPRQVAQTLQA	59	E2	NVIMVSAIGNDGPLY
12	A1	AIPRQVAQTLQADVL	60	E1	MVSAIGNDGPLYGTJ
13	B12	RQVAQTLQADVLWQM	61	F12	AIGNDGPLYGTIINNP
14	B11	AQTLQADVLWQMGT	62	F11	NDGPLYGTIINNPADQ
15	B10	LQADVLWQMGTGAN	63	F10	PLYGTIINNPADQMDV
16	B9	DVLWQMGTGANVRV	64	F9	GTLINNPADQMDVIGV
17	B8	WQMGTGANVRVAVF	65	F8	NNPADQMDVIGVGGI
18	B7	GYTGANVRVAVFDTG	66	F7	ADQMDVIGVGGIDFE
19	B6	GANVRVAVFDTGLSE	67	F6	MDVIGVGGIDFEDNI
20	B5	VRVAVFDTGLSEKHP	68	F5	IGVGGIDFEDNIARF
21	B4	AVFDTGLSEKHPFK	69	F4	GGIDFEDNIARFSSR
22	B3	DTGLSEKHPFKNVK	70	F3	DFEDNIARFSSRGMT
23	B2	LSEKHPFKNVKERT	71	F2	DNIARFSSRGMTTWE
24	B1	KHPFKNVKERTNWT	72	F1	ARFSSRGMTTWEPLG
25	C12	HFKNVKERTNWTNER	73	G12	SSRGMTTWEPLGGY
26	C11	NVKERTNWTNERTLD	74	G11	GMTTWEPLGGYGRMK
27	C10	ERTNWTNERTLDDGL	75	G10	TWELPGGYGRMKPDI
28	C9	NWTNERTLDDGLGHG	76	G9	LPGGYGRMKPDIVTY
29	C8	NERLDDGLGHGT	77	G8	GYGRMKPDIVTYGAG
30	C7	TLDDGLGHGT	78	G7	RMKPDIIVTYGAGVRG
31	C6	DGLGHGT	79	G6	PDIVTYGAGVRGSGV
32	C5	GHGT	80	G5	VTYGAGVRGSGVKGG
33	C4	TFVAGVIASMRECQG	81	G4	GAGVRGSGVKGGCRA
34	C3	AGVIASMRECQGFAP	82	G3	VRGSGVKGGCRALSG
35	C2	IASMRECQGFAPDAE	83	G2	SGVKGGCRALSGTSV
36	C1	MRECQGFAPDAELHI	84	G1	KGGCRALSGTSVASP
37	D12	CQGFAPDAELHI	85	H12	CRALSGTSVASPVVA
38	D11	FAPDAELHI	86	H11	LSGTSVASPVAGAV
39	D10	FRVFTNNQVSYT	87	H10	TSVASPVAGAVTLL
40	D9	DAELHI	88	H9	ASPVAGAVTLLVSTVQK
41	D8	FRVFTNNQVSYT	89	H8	VVAGAVTLLVSTVQK
42	D7	FTNNQVSYT	90	H7	GAVTLLVSTVQKREL
43	D6	FTNNQVSYT	91	H6	TLLVSTVQKRELVNP
44	D5	FTNNQVSYT	92	H5	VSTVQKRELVNPASM
45	D4	FTNNQVSYT	93	H4	VQKRELVNPASMQQA
46	D3	FTNNQVSYT	94	H3	RELVNPASMQALIA
47	D2	FTNNQVSYT	95	H2	VNPASMQALIASAR
48	D1	FTNNQVSYT	96	H1	ASMKQALIASARRLP

FIG. 8A

97	I12	IKDFHVYFRESRDA
98	I11	DAELHIFRVFTNNQV
99	I10	KQALIASARRLPGVN
100	I9	LIASARRLPGVNMFE
101	I8	SARRLPGVNMFEQGH
102	I7	RLPGVNMFEQGHGKL
103	I6	GVNMFEQGHGKLDLL
104	I5	MFEQGHGKLDLLRAY
105	I4	QGHGKLDLLRAYQIL
106	I3	GKLDLLRAYQILNSY
107	I2	DLLRAYQILNSYKPQ
108	I1	RAYQILNSYKPQASL
109	J12	QILNSYKPQASLSPS
110	J11	NSYKPQASLSPSYID
111	J10	KPQASLSPSYIDLTE
112	J9	ASLSPSYIDLTECPY
113	J8	SPSYIDLTECPYMW
114	J7	YIDLTECPYMW
115	J6	YCSQPI
116	J5	CPYMW

**FIG. 8B**